stockrowAlvotech
ALVO Healthcare Drug Manufacturers Specialty & Generic
Alvotech’s revenue for fiscal 2025 (year ended December 2025) was $586.3 million, up 19.7% from fiscal 2024.
- Revenue
- +2,311.0%
- EPS
- −99.5%
- Free cash flow
- −496.6%
- Total debt
- +16.8%
Quarter to June 2026, against a year earlier
Follow ALVO
Alert me
Alvotech (ALVO) EV/Sales
As of 5 November 2026, Alvotech (ALVO) trades at a EV/Sales of 8.6×. Over the past ten years it has ranged from 0.0× (March 2023) to 89.9× (February 2024); the current reading is higher than 47% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.9× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 13.5× | (76.36%) |
| FY2024 | 57.0× | (11.47%) |
| FY2023 | 64.4× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | 7.7× | (61.24%) |
| Mar 2025 | 19.8× | (62.65%) |
| Mar 2024 | 53.1× | 1.03% |
| Sep 2023 | 52.6× | 15.18% |
| 5 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PRGO Perrigo Company plc compare | 1.2× |
| PAHC Phibro Animal Health Corporation compare | 1.4× |
| ANIP ANI Pharmaceuticals, Inc. compare | 1.6× |
| TRLV Trulieve Cannabis Corp. compare | 2.0× |
| PCRX Pacira BioSciences, Inc. compare | 2.3× |
| BCRX BioCryst Pharmaceuticals, Inc. compare | 2.5× |
| XERS Xeris Biopharma Holdings, Inc. compare | 6.7× |
| ALVO Alvotech | 8.6× |
| ETON Eton Pharmaceuticals, Inc. compare | 9.4× |
| Drug Manufacturers Specialty & Generic industry median | 2.9× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)